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ABSTRACT 62 
Hyperemesis Gravidarum (HG), severe nausea/vomiting in pregnancy (NVP), can 63 
cause poor maternal/fetal outcomes. Genetic predisposition suggests the genetic 64 
component is essential in discovering an etiology. We performed whole-exome 65 
sequencing of 5 families followed by analysis of variants in 584 cases/431 controls. 66 
Variants in RYR2 segregated with disease in 2 families. The novel variant L3277R 67 
was not found in any case/control. The rare variant, G1886S was more common in 68 
cases (p=0.046) and extreme cases (p=0.023). Replication of G1886S using 69 
Norwegian/Australian data was supportive. Common variants rs790899 and 70 
rs1891246 were significantly associated with HG and weight loss. Copy-number 71 
analysis revealed a deletion in a patient. RYR2 encodes an intracellular calcium 72 
release channel involved in vomiting, cyclic-vomiting syndrome, and is a thyroid 73 
hormone target gene. Additionally, RYR2 is a downstream drug target of Inderal, 74 
used to treat HG and CVS. Thus, herein we provide genetic evidence for a pathway 75 
and therapy for HG.  76 
 77 
 78 
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INTRODUCTION 81 
Nausea and vomiting of pregnancy is a common symptom affecting 70% of pregnant 82 
women (Goodwin, 1998).  Clinical intervention is necessary in the severest form, 83 
Hyperemesis Gravidarum (HG), which affects up to 2% of pregnancies 84 
(Christodoulou-Smith et al., 2011). HG leads to significant weight loss, dehydration, 85 
electrolyte imbalance, and ketonuria (Fairweather, 1968; Goodwin et al., 1992; 86 
Goodwin, 1998). Although maternal mortality is rare, 6 deaths due to HG have been 87 
reported recently (MacGibbon et al., 2015), as well as morbidity including 88 
Wernicke’s encephalopathy (Chiossi et al., 2006), acute renal failure (Hill et al., 89 
2002), liver function abnormalities (Ahmed et al., 2013), splenic avulsion (Nguyen 90 
et al., 1995), esophageal rupture (Woolford et al., 1993), pneumothorax (Schwarz et 91 
al., 1994), and post-traumatic stress symptoms (Christodoulou-Smith, 2011). HG is 92 
also associated with poor fetal/child outcomes including a 4-fold increased risk of 93 
preterm birth and a 3-fold increased risk of neurodevelopmental delay in children 94 
(Fejzo et al., 2013; Fejzo et al., 2015). 95 
A variety of potential causative factors have been investigated, but the etiology 96 
remains unknown. Evidence for a genetic predisposition is provided by classic twin 97 
studies of Norwegian, Spanish, and Finnish cohorts (Colodro-Conde et al., 2016; 98 
Corey et al., 1992). Family based studies provide evidence that female relatives of 99 
patients with HG are more likely to be affected, with a 17-fold increased risk if a 100 
sister has HG (Gadsby et al., 1993; Vellacott et al., 1998; Vikanes et al., 2010; Zhang 101 
et al., 2011). Recently, mutations in the thyrotropin receptor gene have been linked 102 
to hyperemesis gravidarum accompanied by gestational thyrotoxicosis. This 103 
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suggests a genetic etiology has already been identified in, at minimum, a subgroup 104 
of cases (Coulon et al., 2016). Thus, understanding the genetic component is 105 
essential in discovering the causal pathway(s).  106 
The objective of this study was to perform whole-exome sequencing on HG families 107 
to identify rare variants conferring susceptibility to HG and to validate these 108 
findings in a large cohort of affected and unaffected individuals from the United 109 
States, followed by replication in cohorts from Australia and Norway.  110 
 111 
MATERIALS AND METHODS 112 
 113 
POPULATIONS 114 
The size and minimum HG CASE and CONTROL criteria for the 3 populations (US, 115 
Norway, Australia) used in this study are summarized in Figure 1A.  The genetic 116 
analysis methods used on each population are summarized in Figure 1B.   117 
 118 
US Population  119 
Eligibility Criteria.  The source population for HG CASES in the US included 120 
patients primarily recruited through advertising on the HER Foundation website 121 
(www.helpher.org). The stringent study criteria were designed to exclude all cases 122 
and controls that would increase phenotypic uncertainty. Briefly, the inclusion 123 
criteria for affected individuals were a diagnosis of HG and treatment with 124 
intravenous (IV) fluids or total parenteral nutrition/nasogastric feeding tube. Each 125 
participant was asked to recruit a non-blood related acquaintance with at least 2 126 
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pregnancies that went beyond 27 weeks. Controls were eligible if they experienced 127 
normal or no nausea/vomiting in their pregnancy, no weight loss due to 128 
nausea/vomiting and no medical attention in their pregnancy due to 129 
nausea/vomiting. Participants were enrolled in the family study if an HG CASE had 2 130 
or more additional family members with HG. Additional affected family members 131 
were eligible if they reported severe NVP accompanied by > 5% weight loss, and 132 
medication or hospitalization for HG. Control family members had the same 133 
eligibility requirements as Controls. 134 
 135 
Description of US Families Analyzed by Whole-exome Sequencing and Sanger 136 
sequencing.  The whole-exome sequencing study included 15 affected individuals 137 
and 3 unaffected individuals.  These 18 individuals came from 5 families (Figure 138 
1A).  Follow-up analysis to confirm segregation in Family 1 included additional 139 
family members -3 unaffected and 1 affected individual from Family 1. Each family 140 
submitted saliva samples for a minimum of three affected individuals.  We chose to 141 
analyze a total of 18 individuals: 3 affected individuals from each of 5 families with 142 
HG in addition to 3 unaffected controls from 3 of the five families to further limit 143 
potential causal variants by dismissing those variants identified in unaffected family 144 
members. Pedigrees of two families of Caucasian/European descent analyzed in this 145 
whole-exome sequencing study, and whose variants are described herein, are 146 
shown in Figure 2. Family 1 is of mixed Finnish, Swedish, English, and German 147 
descent. We collected DNA from 4 CASES (4 sisters) and 4 CONTROLS (2 sisters, 148 
mother, and maternal aunt) from Family 1. This family consists of 9 sisters, 5 149 
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affected and 4 unaffected, but only those siblings who participated are shown in 150 
Figure 2A. Family 2 is of mixed Scottish, German, Swiss, English, and Italian descent 151 
and we collected DNA from 3 affected sisters (Figure 2B).  152 
 153 
Description of US CASE/CONTROL Population Analyzed by Genotyping and 154 
Copy-Number Analysis. The follow-up CASE/CONTROL population from the United 155 
States included 584 HG CASES and 431 unaffected CONTROLS that were all 156 
genotyped. A subgroup analysis was performed comparing the most severe HG 157 
CASES requiring total parenteral nutrition/nasogastric feeding tube to Controls who 158 
reported no NVP in any pregnancy.  The subgroup was also used for a copy-number 159 
analysis. All participants gave informed consent. This study was approved by the 160 
UCLA Institutional Review Board.  161 
 162 
Norwegian Population 163 
Eligibility Criteria.  Eligibility was determined using data obtained from self-164 
reported questionnaires (Nilsen et al., 2009). HG CASES were eligible if they were 165 
admitted to hospital for prolonged nausea and vomiting in pregnancy.  Controls 166 
were eligible if they were NOT admitted to hospital for prolonged nausea and 167 
vomiting of pregnancy.   168 
 169 
Description of Norwegian Population Analyzed by GWAS and Correlation with 170 
Weight Loss.  The samples in this HG study included 385 HG CASES and 2280 171 
unaffected Controls. The samples included were singleton pregnancies of 172 
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Norwegian ancestry.  Summary statistics for RYR2 were analyzed for independent 173 
replication in the Norwegian Mother and Child Cohort Study (MoBa), a prospective 174 
population-based pregnancy cohort conducted by the Norwegian Institute of Public 175 
Health recruited from Norway during 1999-2008 (http://www.fhi.no/moba-en; 176 
Magnus et al., 2016). In addition, data was collected for each participant on maternal 177 
pre-pregnancy weight and weight change until week 18 of gestation and used as a 178 
continuous variable in a regression analysis to study genetic associations with 179 
weight loss in early pregnancy.  Ethical approval for the MoBa study has been 180 
approved by the Regional Committee for Medical Research Ethics and all women 181 
provided informed written consent.  182 
 183 
Australian Population 184 
Eligibility Criteria. Eligibility was determined using data collected from health and 185 
wellbeing surveys.  Women reported their experience in their pregnancy with the 186 
most severe NVP using a five-point questionnaire adapted from Zhang et al (2011).  187 
HG CASES (1) were defined as NVP that disrupted daily routine accompanied by 188 
weight loss and medication and/or IV fluids and/or feeding tube.  A second less 189 
stringent CASE criteria included HG CASES (1) in addition to HG CASES (2) that 190 
reported NVP that disrupted their daily routine and medication treatment, but did 191 
not lose weight.  CONTROLS were defined as experiencing no NVP.   192 
Women in between the extreme ends who reported MILD NVP (NVP for more than 7 193 
days, but did not see a doctor or nurse/did not disrupt daily routine very much) and 194 
MODERATE NVP (disrupted daily routine but it did not affect my weight and did not 195 
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need medication, were not included in the CASE: CONTROL study, but were included 196 
in a continuous analysis of the GWAS data. 197 
 198 
Description of Australian Population GWAS Analyzed using CASE:CONTROL 199 
and Continous Phenotype. The Australian sample is composed of genotyped 200 
women unselected for HG who are part of the Australian Endogene Study and the 201 
QIMR Mothers of Twins Study, which are two of the cohorts participating in the NVP 202 
Genetics Consortium (Colodro-Conde; 2016). 203 
As part of health and wellbeing surveys, a total of 1440 women reported on NVP 204 
severity.   We conducted a CASE:CONTROL analysis using 946 women who were in 205 
the extremes of the severity scale. Women reporting no NVP (n=677) were used as 206 
controls and women reporting severe NVP (n=269) with disruption of their daily 207 
routine and medication prescription, including those losing weight and put on a drip 208 
or feeding tube, were used as CASES.   We also conducted a more stringent 209 
CASE/CONTROL analysis that excluded the 139 HG CASES with no weight loss, thus 210 
limiting the study to 130 HG CASES and 677 CONTROLS.   Finally, we analyzed NVP 211 
as a continuous phenotype for all 1440 study participants, which included an 212 
additional 163 CASES of MILD NVP and 331 CASES of MODERATE NVP.  213 
 214 
GENETIC METHODS 215 
Genetic Methods for US Population 216 
Whole-Exome Sequencing of Families. Each study participant was asked to 217 
submit a saliva sample for DNA analysis.  A saliva collection kit (Oragene, Ottawa, 218 
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Canada) was self-administered for submitting 2 milliliters of saliva. DNA was 219 
extracted from 75% of the saliva sample according to the manufacturer’s 220 
instructions (Oragene, Ottawa Canada).  221 
We sequenced the entire exomes (~50 Mb) of 15 affected individuals and 3 222 
unaffected individuals from 5 HG families. Paired end reads 100 nucleotides (2 X 223 
100 nucleotides) were generated on an Illumina HiSeq 2000. Each sample was 224 
sequenced on 3 different lanes to avoid lane bias. Qseq files were converted into 225 
Sanger-formatted FASTQ files and reads were mapped to the reference human 226 
genome build hg19 using the Burrows Wheeler Alignment algorithm (BWA) (Li and 227 
Durbin, 2009). Duplicated reads were marked by Picard. The Genome Analysis 228 
Toolkit (GATK) was used for local realignment around indel sites followed by a base 229 
quality recalibration (McKenna et al., 2010). For reliable SNP calling we used 230 
genotype quality ≥ 10; read QUAL ≥ 30 and a minimum read depth of 4. The 231 
combined total variants from all 18 individuals were filtered as shown in Figure 3. 232 
Synonymous variants, which are unlikely to be causal, were discarded. The 233 
identified variants were further filtered against variants present in the HapMap, 234 
1000 Genomes Project and dbSNP132 databases, selecting for novel variants and 235 
known variants with minor allele frequency <5% (McKenna et al., 2010; 236 
International HapMap 3 Consortium et al., 2010). These variants were further 237 
filtered by selecting variants predicted to affect protein function using PolyPhen and 238 
SIFT (Ramensky et al., 2002, Ng and Henikoff, 2003). Variants were further filtered 239 
by deleting variants present in the 3 unaffected family controls. All variants were 240 
discarded that were not shared by all 3 whole-exome sequenced affected family 241 
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members with each family. Finally, we identified a subgroup of genes involved in 242 
more than one family, and screened these genes for a functional effect, which 243 
included genes 1) functionally relevant to reproduction (ie hormones), 2) nausea 244 
and vomiting (ie gastric tract, vomiting center of the brain), and 3) genes expressed 245 
in relevant tissues (ie ovary, placenta, vomiting center of the brain).    246 
 247 
Sanger Sequencing to analyze segregation in Family 1. Sanger Sequencing of the 248 
novel variant in Family 1 (RYR2 exon68:c.T9830G:p.Leu3277Arg) was performed to 249 
confirm whole-exome sequencing results and to confirm or deny segregation with 250 
the disease in the remaining family members who were not included in exome 251 
sequencing (1 affected sister and 1 unaffected sister, the unaffected mother, and an 252 
unaffected maternal aunt). PCR primer pairs GGAAGTCATACTGCCCATGC and 253 
GGGGTACAATGTCTTCTTCCA were designed from genomic DNA to amplify and 254 
sequence the variant. PCR amplification and sequencing were carried out using 255 
standard methods.  256 
 257 
Protein prediction tools used to predict functional effect of L3277R. The SIFT 258 
protein prediction tool was used to determine that the novel SNP encoding L3277R 259 
resulted in a damaging protein product, and the Provean Prediction tool was used to 260 
determine that it was deleterious. (Choi et al., 2012; Ng and Henikoff, 2003).  261 
 262 
Genotyping. Taqman primers were designed for both the novel variant L3277R in 263 
Family 1 and the rare variant G1886S identified in Family 2, and used to screen 264 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
    
 
12
12
individuals from > 573 HG CASES and > 426 controls using Applied Biosystems 265 
PRISM 7900HT Sequence Detection System (TaqMan) for large-scale screening. The 266 
call rate was > 96%.  267 
 268 
Statistical Analysis. Statistical significance of association of genotype with HG was 269 
determined by calculating the p-values using a 1-tailed Fisher’s exact test 270 
(http://graphpad.com/quickcalcs/contingency1/) and odds ratios were calculated 271 
using the odds ratio calculator (https://www.medcalc.org/calc/odds_ratio.php).  A 272 
p-value <0.05 was considered statistically significant.   273 
 274 
Copy-number analysis of RYR2. Quantitative real-time PCR analysis of RYR2 was 275 
performed in triplicate on 10 ng from 240 DNA samples (101 extreme CASES 276 
requiring tube feeding and 139 extreme controls with no nausea/vomiting in > 2 277 
pregnancies) on 384-microwell optical plates using the predesigned Taqman Copy 278 
Number Assay covering 90 base pairs within a likely pathogenic duplicated region 279 
in autism (Soueid et al., 2016) (Assay ID: Hs00137466_cn FAM labeled, MGB probe, 280 
Thermofisher Scientific, Waltham, MA) and the RNaseP Copy Number Reference 281 
Assay (VIC labeled, TAMRA probe). Melt-curve analysis was applied and all results 282 
were normalized to RNaseP levels and calculated using the ΔΔCT method. One 283 
sample with a deletion originally identified in the above triplicate assay along with 5 284 
normal control samples, were assayed a second time in duplicate (re-diluted to 10 285 
ng from the original DNA sample) to verify the deletion.  286 
 287 
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 288 
Genetic Methods for Norwegian Population. Maternal genome-wide data were 289 
obtained using Illumina HumanCoreExome genotyping BeadChip v1.1. Imputation 290 
was performed with reference panel HapMap phase 3 build 36 using IMPUTE2 291 
(Howie et al., 2009). Standard association analyses were performed in PLINK 1.7 292 
(Purcell et al., 2007). Genotypes were analyzed with allelic and genotypic approach. 293 
Regression analysis was performed using a z-score transformed gestational weight 294 
gain (GWG) based on maternal pre-pregnancy weight and weight change until week 295 
18 of gestation. 296 
 297 
Genetic Methods for Australian Population. The samples were genotyped using 298 
Illumina arrays and genotype imputation was completed using 1000 Genome Phase 299 
3 version 5 as reference data. For validation of the rare imputed SNP G1886S, we 300 
also conducted CASE/CONTROL analysis in a more stringent subset by removing the 301 
participants who did not report weight loss from the CASES, thus limiting to a more 302 
stringent CASE phenotype (n=130). 303 
 304 
RESULTS 305 
 306 
Whole-exome sequencing identifies RYR2 variants linked to HG in 2 of 5 307 
families. We sequenced the entire exomes (~50 Mb) of 15 affected individuals and 308 
3 unaffected individuals from 5 families with HG. The mean coverage was 54 fold. 309 
Reads were mapped to the human genome reference build UCSC hg19 using BWA 310 
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(Li and Durbin, 2009). On average, 3223 single-nucleotide variants were detected in 311 
each individual and a total of 58006 variants were detected in all 5 families 312 
combined (Figure 3). The synonymous variants were subsequently discarded 313 
resulting in 29856 variants. The identified variants were further filtered against 314 
variants present in the HapMap, 1000 Genomes Project, and dbSNP132 databases, 315 
resulting in 13509 novel variants and known variants with minor allele frequency 316 
<5% (McKenna et al., 2010; International HapMap 3 Consortium et al., 2010). These 317 
variants were further filtered by selecting variants predicted to affect protein 318 
function using PolyPhen and SIFT (Ramensky et al., 2002; Ng and Henikoff, 2003). 319 
Filtering for missense and stop gain or stop loss variants that were shared by any of 320 
the 3 whole-exome sequenced unaffected family members resulted in 6481 variants. 321 
 322 
As we did not find any single variant that was shared by all the affected members 323 
across all of the families, we focused on variants within each family shared by all 3 324 
whole-exome sequenced affected subjects. For example, 94 variants were shared by 325 
all 3 affected individuals in Family 1, and 227 variants were shared by all 3 affected 326 
individuals in Family 2. We searched for variants and/or genes that were shared by 327 
more than one family. 27 genes were identified that carried rare variants in the 328 
affected family members in more than one family. These variants were evaluated 329 
based on a functional effect, which included variants located in genes functionally 330 
relevant to reproduction (ie hormones), nausea and vomiting (ie gastric tract, 331 
vomiting center of the brain), and genes expressed in relevant tissues (ie ovary, 332 
placenta). This resulted in identification of the gene RYR2 involved in 2 of 5 families 333 
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as a strong candidate based on its functional potential: RYR2 encodes an 334 
intracellular calcium release channel that is part of a signaling pathway for emesis 335 
expressed in the vomiting center of the brain (Giannini et al., 1995; Zhong et al., 336 
2014). It is the only gene identified with variants significantly linked to cyclic 337 
vomiting syndrome, is a thyroid hormone target gene, and is differentially expressed 338 
in cumulus cells of the pre-ovulatory follicle (Grøndahl et al., 2012; Jiang et al., 2000; 339 
Li et al., 2015).  340 
Synonymous and common variants in RYR2 that were originally removed in the 341 
filtering steps were re-investigated.  None of the 6 variants identified segregated 342 
with disease. In addition, variants in RYR2 in the remaining families (Family 3,4,5) 343 
were not identified in this study. Potentially causal variants in other genes in the 344 
remaining families are currently under investigation.   345 
 346 
Genotyping the novel and rare RYR2 variants in the US cohort provides 347 
confirmation. In the largest HG family (Family 1), the novel heterozygous variant in 348 
the RYR2 gene (RYR2:NM_001035:exon68:c.T9830G:p.Leu3277Arg) was confirmed 349 
by Sanger Sequencing to be shared by four affected sisters and was not shared by 350 
either of 2 unaffected sisters, the unaffected mother, nor the unaffected maternal 351 
aunt (Figure 2A).  The phenotype and genotype results suggest L3277R is of 352 
paternal rather than maternal origin in this family.  However, the DNA from the 353 
father who is presumed to be a carrier, nor his sister who reportedly did not have 354 
HG, was unfortunately not available.  We do not have any additional information 355 
about phenotype on the father’s side (ie father’s mother).  Genotyping via Taqman 356 
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showed the RYR2 variant to be unique in the sample to Family 1, as it was not 357 
identified in 584 HG CASES and 431 unaffected CONTROLS (Table 1). The nucleotide 358 
at the location of L3277R is 100% conserved across vertebrates and invertebrates. 359 
The mutation changes a hydrophobic amino acid to an electrically charged amino 360 
acid, and is predicted to be damaging and deleterious (SIFT Prediction Score=0; 361 
Provean Prediction Score=-5.38).  362 
In Family 2, the heterozygous variant G1886S 363 
RYR2:NM_001035:exon37:c.G5656A:p.Gly1886Ser rs3766871 was shared by all 3 364 
affected sisters (Figure 2B). Genotyping via Taqman identified the heterozygous 365 
variant G1886S (Family 2) to be twice as common (p=.046) in CASES than 366 
CONTROLS (in 38 out of 580 additional CASES and 17 out of 431 CONTROLS) and 367 
four times more common (p=.023) when comparing the extreme ends of the clinical 368 
spectrum, 9 out of 106 CASES requiring tube feeding compared to 3 out of 141 369 
controls who reported no nausea/vomiting in pregnancy) (Table 1). The SNP 370 
G1886S is already known to have a biological effect in the homozygous state. 371 
Homozygous substitution of serine for glycine causes a significant increase in 372 
cellular calcium oscillation activity compared to wild-type RYR2 in HEK293 cells 373 
(Koop et al., 2008). Interestingly, calcium oscillations are completely abolished by 374 
homozygous substitution of a neighboring SNP in the double mutant 375 
G1885E/G1886S. The estimated frequency of G1886S in the European_American 376 
population (ESP6500) is 0.031 and the estimated frequency of G1885E is 0.023 (The 377 
1000 Genomes Project Consortium, 2015).  Therefore the estimated frequency of 378 
carrying both mutations is very rare (<0.001), but may be selected for in the 379 
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extreme control population where the phenotype (no NVP in at least 2 pregnancies) 380 
is also rare.   The SNP G1886S has also been associated with ventricular arrhythmias 381 
and is an independent predictor of sudden cardiac death, while a neighboring SNP 382 
rs790896 (G>A) was linked to a decreased risk of sudden cardiac death (Ran et al., 383 
2010).   The frequency of the protective A allele rs790896 is predicted to be 0.415 in 384 
the European population (The 1000 Genomes Project Consortium, 2015), so the 385 
estimated frequency of carrying both G1886S and rs790896 is 0.013. In this study 386 
we identified 3/141 extreme controls carrying G1886S and 2 cases of 387 
G1886S/rs790896 are predicted in 141 extreme controls.  Therefore, it will be 388 
interesting to investigate if additional variants in controls carrying RYR2 G1886S 389 
(such as G1885E and rs790896) explain why this variant is also present in a subset 390 
of controls with no NVP. 391 
 392 
Summary statistics were supportive but not statistically significant for variant 393 
G1886S in RYR2 in both a Norwegian and an Australian GWAS. Genotype data 394 
for G1886S were imputed in both Norwegian and Australian datasets. Although 395 
statistical significance was not achieved probably due to the rarity of G1886S and 396 
the small number of affected individuals, there is a supportive trend in both cohorts. 397 
In the Norwegian cohort there is a 1.3-fold OR for this SNP (reference allele A), and 398 
in the Australian cohort, after removal of the CASES with no weight loss to better 399 
reflect the severe end of the clinical spectrum of NVP, there was a 1.2-fold OR for 400 
G1886S (Table 1).  401 
 402 
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Common variants in RYR2 (rs790899 and rs1891246) are significantly linked 403 
to HG and are highly significant with respect to weight loss in early pregnancy.   404 
In addition to the rare variants, common RYR2 SNPs (rs790899 and rs1891246) 405 
were significantly linked to HG in both the Norwegian and Australian GWAS using 406 
the CASE/CONTROL phenotypes (Table 1). No other common variants were 407 
identified that reached statistical significance in both the Norwegian and Australian 408 
datasets. 409 
In the Norwegian dataset, adding the zscore for weight change until gestational 410 
week 18 as a covariate increased the odds ratio and significance for the common 411 
RYR2 variants, and suggested a strong association with weight loss (p=2.12E-31 for 412 
rs790899 and p=1.19E-31 for rs1891246, Table 2A). In the smaller Australian 413 
dataset, using the continuous severity measure, neither rs790899 nor rs1891246 414 
reached statistical significance.  415 
 416 
Copy-number analysis identifies a deletion in RYR2 in an extreme HG CASE 417 
requiring intravenous feeding (TPN). We also performed copy-number analysis 418 
to search for pathogenic duplications and/or deletions in RYR2. A deletion in exon 419 
16 was identified in RYR2 in DNA from one woman with HG requiring total 420 
parenteral nutrition (TPN) among DNA isolated from 101 CASES requiring TPN for 421 
severe HG (Table 1). The deletion was not observed in any of the remaining samples 422 
including 139 extreme controls reporting no nausea and no vomiting in any of their 423 
pregnancies. 424 
 425 
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DISCUSSION 426 
 427 
This is the first whole-exome association study of HG and suggests RYR2 may play a 428 
role in the biology of HG. We have successfully identified two rare variants in RYR2 429 
that are linked to HG using a whole-exome sequencing approach followed by 430 
genotyping a large validation cohort from the US. Independent replication in GWAS 431 
studies from Norway and Australia are suggestive of a role for RYR2 and revealed 2 432 
common variants very significantly associated with weight loss in early pregnancy. 433 
Copy-number screening identified a deletion in RYR2 in an extreme HG CASE 434 
requiring intravenous feeding.  435 
RYR2 encodes an intracellular calcium release channel which localizes to the 436 
intracellular Ca2+ stores (ER/SR), and that, in excitable cells, including cardiac 437 
muscles and neurons, controls contraction and activity, respectively (Santulli and 438 
Marks, 2015). RYR2 is expressed in several other cell types in many tissues, 439 
including the thyroid gland, ovaries, and pancreas (Craps et al., 2015; Grøndahl et 440 
al., 2012; Santulli et al., 2015).  An animal model of emesis shows that intracellular 441 
Ca2+ release through ryanodine receptors in the brainstem initiate Ca2+-dependent 442 
activation of CaMKIIa and ERK1/2, leading to emesis, which can be blocked by 443 
dantrolene, an inhibitor of emesis (Zhong et al., 2014). Thus, we speculate that the 444 
variants and deletions described here may result in abnormalities in the emesis-445 
signaling pathway via a hyper-functioning Ca2+ channel. Indeed, variants in RYR2, 446 
including G1886S identified in this study (albeit in a heterozygous state), have been 447 
shown to cause increased RYR2 channel activity in a homozygous state (Koop et al., 448 
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2008). Functional evidence for the other variants identified in this study remains to 449 
be determined, but there are some clues.  The novel variant L3277R is predicted to 450 
be deleterious and map between a putative phosphorylation site (AA2947) and a 451 
CALM interacting site (AA3581). And exon 16, the location of the deletion, contains, 452 
an RIH Domain (CDD:250561) which may form a binding site for IP3.   The common 453 
variants identified in this study (rs790899 and rs1891246) both map in introns 454 
toward the end of the gene in sites with no predicted regulatory significance (Kent 455 
et al., 2002), and therefore, are not likely to have a phenotype on their own, but may 456 
be linked to functional mutations/deletions not identified in this study.  457 
The role RYR2 variants play in HG etiology is unknown, but there are several 458 
intriguing avenues to explore further. Firstly, RYR2 encodes an intracellular calcium 459 
release channel that is the only ryanodine receptor expressed in the vomiting center 460 
of the brain (Giannini et al., 1995) and has been implicated in a signaling pathway 461 
underlying emesis in an animal model (Zhong et al., 2014). Secondly, the thyroid 462 
hormone has been shown to induce RYR2 overexpression (Jiang et al., 2000), while 463 
the drug Inderal (Propranolol, used to treat hyperthyroidism) blocks RYR2 464 
phosphorylation and lowers its expression (Yoshida et al., 1992). Hyperthyroidism 465 
accompanies HG in as many as 60% of pregnancies (Goodwin et al., 1992) and 466 
mutations in the thyrotropin receptor have been linked to HG (Coulon et al., 2016), 467 
providing additional genetic evidence that this pathway may be causal in some 468 
cases.  However, because thyrotoxicosis is not normally associated with nausea and 469 
vomiting, it is likely that another factor is involved, such as the additional 470 
requirement of an emetic stimulus (ie pregnancy hormones).  There could be a 471 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
    
 
21
21
viscious cycle of deterioration from NVP to HG as a result of hormone-induced 472 
nausea/vomiting in conjunction with aberrant RYR2 Ca2+ signaling caused by 473 
progressive thyroid dysfunction and/or mutant RYR2.  Of note, two of 6 recent 474 
maternal deaths secondary to HG were accompanied by severe 475 
thyrotoxicosis/thyroid storm (Knight et al., 2014; MacGibbon et al., 2015). Thirdly, 476 
in a NextGen sequencing study of Cyclic Vomiting Syndrome (CVS), RYR2 was the 477 
only gene among over 1,000 genes screened, with variants significantly linked to the 478 
disease (Lee et al., 2015), and Inderal has been used to effectively treat 92% of 479 
children with CVS (Haghighat et al., 2007). Likewise, in 1980 a patient presenting 480 
with severe thyrotoxicosis and hyperemesis gravidarum reportedly responded 481 
dramatically to Inderal treatment (Valentine et al., 1980). As her thyroid function 482 
improved and the Inderal was discontinued, she again returned to the hospital with 483 
severe vomiting. Upon restarting medication, her vomiting ceased and she 484 
continued treatment until term.  Our findings provide evidence for a biological 485 
pathway, diagnostic marker, and potential targeted therapy for the etiology and 486 
treatment of HG.  487 
Lastly, limited evidence suggests RYR2 may play a role in fertility. It is expressed 488 
more than 50-fold in cumulus cells compared to mural granulosa cells of human pre-489 
ovulatory follicle, and its expression correlates with amphiregulin, a key mediator of 490 
the effect of LH/hCG and a marker for oocyte competence (Grøndahl et al., 2012). 491 
Ryanodine receptor variants are significantly associated with pig litter size (Omelka 492 
et al., 2004), and women with HG produce an abnormally high number of mature 493 
oocytes when undergoing follicle stimulation (Fejzo et al., 2010). A genetic link that 494 
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explains both the symptoms of HG and a potential increase in fertility, would 495 
provide a rationale for why severe nausea in pregnancy has not been selected out in 496 
nature despite its link to adverse outcomes. 497 
The limitation of this study stems from the fact that full sequencing and copy 498 
number analysis of RYR2 in all cases and controls, is cost-prohibitive. We were only 499 
able to study the 2 mutations involved in the 2 HG families in this study, not the 500 
complete gene sequence, in the validation cohorts from the United States. Also, 501 
while the US cohort used intravenous fluid treatment as its clinical criteria for HG, 502 
and the Norwegian cohort used hospitalization, the Australian cohort used a less 503 
severe phenotype, which may have led to a reduced effect for that dataset.  The 504 
small sizes for GWAS may also contribute to an underestimate of the effect for the 505 
validation cohorts.  Alternatively, the multiple analyses in different relatively small 506 
cohorts can lead to over-interpretation of the results. Finally, the copy-number 507 
analysis that identified a deletion only surveyed 90 bp of exon 16 in 240 individuals. 508 
Mutation and copy-number analysis of the full RYR2 gene in cases and controls is 509 
now warranted to determine their frequencies in affected individuals and to 510 
understand the role of RYR2 in HG pathogenesis.  511 
In conclusion, this study uses an innovative approach to identifying the etiology of 512 
HG.  This disease has thus far eluded both scientists and clinicians, resulting in 513 
largely ineffective treatments, significant maternal morbidity, and an increased risk 514 
in adverse fetal outcome (Fejzo et al., 2013). Mutations in genes in the ryanodine 515 
receptor-signaling pathway may account for a substantial amount of the attributable 516 
risk of HG, although just how much must be deferred to a follow-up study as 517 
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causality has not been definitively established. Additional studies are required, such 518 
as functional analysis of the deleterious RYR2 variant L3277R, complete deletion 519 
analysis of RYR2, and a larger GWAS. However, this novel discovery may provide the 520 
first step in understanding the etiology of HG. The identification of genes linking HG 521 
to RYR2 provides an intriguing new avenue for diagnosis, research, and therapy.  522 
523 
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FIGURE 1.  Summary of A) Populations and B) Methods used in this study. The 759 
size and minimum HG CASE and CONTROL criteria for the 3 populations (US, 760 
Norway, Australia) used in this study are summarized in Figure 1A.  The genetic 761 
analysis methods used on each population are summarized in Figure 1B.  *MILD 762 
NVP was defined as participants who answered: ‘had some NVP for more than 7 763 
days, but did not see a doctor or nurse and did not disrupt daily routine very much’ 764 
**MODERATE NVP was defined as ‘disrupted daily routine but did not affect weight 765 
and did not need medication’. 766 
 767 
 768 
769 
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FIGURE 2. Pedigrees and Genotypes of A) Family 1 and B) Family 2. In Family 1, 770 
A, B, C, and D all were affected with HG. Participant A reported pic line, medication 771 
and weight loss to treat HG, B reported a 10 pound weight loss and medication to 772 
treat symptoms until birth, C reported intravenous fluids (IV) and a 23 pound 773 
weight loss, and D reported IV fluids, hospitalization, weight loss, and medication to 774 
treat her HG. Among the unaffected family members, participant E reported 2 775 
pregnancies with mild nausea, no weight loss, and no medication; F reported 5 776 
pregnancies with no nausea and vomiting, no weight loss, and no medication in any 777 
pregnancy, G reported 13 pregnancies with normal nausea and vomiting, no weight 778 
loss, no medication, and H reported 3 pregnancies with normal nausea and 779 
vomiting, no weight loss, and no medication. For Family 2, all 3 sisters were affected 780 
and all 3 sisters required medication and IV fluids to treat their HG. Sisters A and C 781 
were both hospitalized for HG. Their mother was also affected but did not 782 
participate. 783 
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Figure 3. Whole-exome sequencing filtering steps identifies RYR2 variants. 785 
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TABLE 1. RYR2 variant table. 788 
RYR2 
VARIANT SOURCE EXON/INTRON METHOD SCREENED 
   
OR 
P-
value 
L3277R* FAMILY 1, USA 
68:c.T9830G 
Genotyping 584 HG, 431 C 
   
NA     NA 
G1886S FAMILY 2, USA 37:c.G5656A Genotyping 584 HG, 431 C 1.29 0.046 
G1886S 
FAMILY 2, 
USA2 37:c.G5656A Genotyping 106 HG, 141 C 4.27 0.023 
G1886S NORWEGIAN 37:c.G5656A GWAS 
318 HG, 1823 
C 1.32 0.661 
G1886S AUSTRALIAN 37:c.G5656A GWAS 269 HG, 677 C 0.89 0.693 
G1886S AUSTRALIAN2 37:c.G5656A GWAS 130 HG, 677 C 1.17 0.665 
rs790899 NORWEGIAN intron 95 GWAS 
385 HG, 2280 
C 1.19 0.033 
rs790899 AUSTRALIAN intron 95 GWAS 269 HG, 677 C 1.33 0.013 
rs1891246 NORWEGIAN intron 100 GWAS 
385 HG, 2280 
C 1.23 0.009 
rs1891246 AUSTRALIAN intron 100 GWAS 269 HG, 677 C 1.3 0.014 
NOVEL DEL* USA 16:237619976 
Copy 
Number 101 HG, 139C NA NA 
HG=Hyperemesis Gravidarum, C=Unaffected Control, TPN=Severe HG requiring tube feeding 
L3277R*=novel deleterious SNP  (c.9830T>G, p.Leu3277Arg)  
*DEL=deletion in exon 16 of unknown size 
rs3766871 G1886S (NM_001035.2:c.5656G>A, NP_001026.2:p.Gly1886Ser) 
rs790899 (NM_001035.2:c.13913+381G>A; XM_006711804.2:c.13943+381G>A) 
rs1891246 (NM_001035.2:c.14434-490T>G; XM_005273224.1:c.14491-490T>G) 
USA2 and AUSTRALIAN2 are datasets with more stringent criteria. 
USA2 (HG=requiring iv feeding, C=no NVP) 
AUSTRALIAN2 (HG=weight loss, C=no NVP) 
789 
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TABLE 2. Adding zscore weight change until gestational week 18 as covariate 790 
shows rs790899 and rs1891246 associated with weight. 791 
CHR SNP BP A1 TEST NMISS OR STAT P-VALUE 
1 rs790899 237957678 C ADD 2499  1.267 2.649 0.00808 
1 rs790899 237957678 C COV1 2499 0.2447 
-
11.66 2.12E-31 
1 rs1891246 237981846 G ADD 2499 1.292 2.968 0.002993 
1 rs1891246 237981846 G COV1 2499 0.2424 
-
11.71 1.19E-31 
rs790899 (NM_001035.2:c.13913+381G>A; XM_006711804.2:c.13943+381G>A) 
rs1891246 (NM_001035.2:c.14434-490T>G; XM_005273224.1:c.14491-490T>G) 
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UNITED STATES
5 HG FAMILIES:
Primary family member: HG diagnosis requiring treatment with IV fluids or feeding tube, and
>2 family members: severe NVP and >5% weight loss/medication or hospitalization for HG
Family 1:  4 HG, 4 C (3 HG, 1 C for whole-exome sequencing; all 8 used for Sanger-sequencing)
Family 2:  3 HG (3 HG for whole-exome sequencing)
Family 3:  3 HG (3 HG for whole-exome sequencing)
Family 4:  3 HG, 1 C (3 HG, 1 C for whole-exome sequencing) 
Family 5:  3 HG, 1 C (3 HG, 1 C for whole-exome sequencing) 
584 HG CASES: HG diagnosis requiring treatment with IV fluids or feeding tube
431 CONTROLS: 2 pregnancies with none/normal NVP, no weight loss, no treatment
NORWAY
385 HG CASES: hospitalized for NVP
2280 CONTROLS: not hospitalized for NVP
AUSTRALIA
130 HG CASES(1): disrupted daily routine/lost weight/medication or IV fluids or feeding tube 
139 HG CASES(2): disrupted daily routine/medication/no weight loss 
677 CONTROLS:  no NVP
FIGURE 1A. POPULATIONS SUMMARY 
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UNITED STATES
WHOLE-EXOME SEQUENCING-15 HG CASES/3 CONTROLS FROM 5 FAMILIES
GENOTYPING IN 584 HG CASES/431 CONTROLS
GENOTYPING IN 106 HG CASES REQUIRING TPN/141 CONTROLS WITH NO NVP
COPY NUMBER ANALYSIS 101 HG CASES REQUIRING TPN/139 CONTROLS WITH NO NVP
NORWAY
GWAS ON 385 HG CASES/2280 CONTROLS, AND
ANALYSIS OF COVARIANCE WITH WEIGHT LOSS UNTIL 18 WEEKS GESTATION 
AUSTRALIA
GWAS ON 269 HG CASES (1 AND 2)/677 CONTROLS
GWAS ON 130 HG CASES(1)/677 CONTROLS
ANALYSIS OF CONTINUOUS PHENOTYPE ADDED 163 MILD* AND 331 MODERATE** NVP CASES
FIGURE 1B. METHODS SUMMARY 
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Family 1
E A B F C D
H G
TT TT
TT GT GT TT GT GT
RYR2:NM_001035:
exon68:c.T9830G:p.Leu3277Arg
Clear   = Unaffected
Grey    = Affected
Figure 2A.
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Family 2
A                B                C
GA GA GA
RYR2:NM_001035: rs3766871 
exon37:c.G5656A:p.Gly1886Ser
Clear   = Unaffected
Grey    = Affected
Figure 2B.
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1. 58006 variants from 18 individuals in 5 families
2. 29856 after removal of synonymous variants
3. 13509 after removal of common variants
4. 9870 after removal of non-damaging variants
5. 6481 after removal of variants in unaffected
6A.  94 variants shared by Family 1 6B. 156 variants shared by Family 2
RYR2 
Figure 3.  Whole-exome sequencing filtering steps
6C.  405 variants in remaining 3 Families
7.  27 Genes with variant(s) segregating in more than one family
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HIGHLIGHTS 
 
• Whole-exome sequencing in Hyperemesis Gravidarum (HG) 
identifies link to RYR2  
• Novel variant L3277R segregates with disease in large HG family 
• US genotyping, and Norwegian and Australian GWAS support link 
to G1886S in RYR2 
• RYR2 deletion identified in severe case treated with total 
parenteral nutrition 
• Common variants rs790899 and rs1891246 significantly 
associated with weight loss 
